Following a dismal 2018, Paratek Pharmaceuticals (PRTK) rallied in January and February 2019, but the selling has since resumed. Those following the name might be wondering if there is anything that can bring about a sustained rally in the stock.
Figure 1: Past 3 years of PRTK trading. Source: YCharts
Clinical and Regulatory Catalysts
PRTK's novel antibiotic Nuzyra (omadacycline) is already approved in the US for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). However, the company is still running mid-stage trials of the drug